Sign In
Buy XOMA
$41.70
+0.0100 (+0.0240%)
At Close: Jun 03, 2026
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
07:30am, Tuesday, 13'th Aug 2024
Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute
My 2 Top Royalty Income Picks, Yields Up To 9.5%
08:30am, Friday, 19'th Jul 2024
My 2 Top Royalty Income Picks, Yields Up To 9.5%
Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?
05:10am, Thursday, 18'th Jul 2024
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares
02:31am, Saturday, 29'th Jun 2024
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs. XOMA's diverse IP portfolio spans various
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
08:55am, Friday, 21'st Jun 2024
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
XOMA Declares Quarterly Preferred Stock Dividends
07:30am, Thursday, 20'th Jun 2024
EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividen
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher
07:30am, Wednesday, 12'th Jun 2024
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Th
3 Crazy Good Stocks to Buy With $500 Right Now
06:00am, Wednesday, 12'th Jun 2024
Although there was a time when the stock market was solely the playground of the wealthy, it no longer takes money to make money on Wall Street. The democratization of investing means even those with
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
07:45pm, Monday, 03'rd Jun 2024
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics,
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
07:30am, Tuesday, 14'th May 2024
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wa
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
07:30am, Thursday, 09'th May 2024
Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:01am, Tuesday, 07'th May 2024
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rear
Actym Therapeutics Appoints Thomas Smart as CEO
09:00am, Wednesday, 24'th Apr 2024
BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
XOMA Corporation Announces Closing of Tender Offer
09:00am, Wednesday, 03'rd Apr 2024
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biote
